This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Medidata Solutions Introduces The Medidata Clinical Cloud Study, Single Study Option For The Industry-Leading Clinical Research Platform

Stocks in this article: MDSO

Medidata Solutions (NASDAQ: MDSO) introduced the Medidata Clinical Cloud™ Study, which brings the industry-leading benefits of Medidata’s cloud-based platform to single studies as an easy-to-acquire, ready-in-weeks option. Providing unified planning, setup and execution of a clinical trial, the offering was unveiled at the Drug Information Association’s (DIA) 49th Annual Meeting, June 23–26 in Boston, MA.

“The Medidata Clinical Cloud Study is an innovative new clinical research solution designed to produce immediate, measurable value by bringing the Medidata Clinical Cloud to a wider set of life sciences organizations,” said Glen de Vries, president of Medidata Solutions. “I’m thrilled to announce it at the DIA Annual Meeting, one of the most exciting and important industry events.”

Medidata also announced its Medidata Patient Cloud™, designed to enhance patients’ participation in clinical trials by allowing them to use their own personal mobile devices with iOS as an input device.

The Medidata Clinical Cloud Study is a comprehensive platform for the unified planning, setup and execution of a clinical trial, designed to be set up in a matter of weeks. Organizations of all sizes–small and mid-sized companies, individual clinical programs and companies looking to try out the Medidata Clinical Cloud—can use this single solution for trial activities including data capture and management, patient randomization, trial supply management, medical coding, patient reported outcomes, risk-based monitoring and business analytics. Medidata’s study design, budgeting and planning, site negotiation, operational trial management and safety capture solutions are also available as part of a Clinical Cloud Study.

The Medidata Patient Cloud brings the patient’s voice to clinical trials with an interface that uses a patient’s own iOS device, with a simplified setup and execution experience for the clinical research team. A seamless application in the Medidata Clinical Cloud, it enables sponsors to save time and money typically associated with device management and provisioning, questionnaire development and implementation, and patient data management and integration. The Patient Cloud is designed to enhance patient participation in clinical trials by letting them provide trial information in ways that are integrated into their daily lives.

At its DIA exhibit booth, Medidata will also be featuring:

  • Integration between ECG and the Medidata platform, with electrocardiograph devices from Spaulding Clinical, a Phase I clinical trial unit and Medidata Technology Partner, allowing sponsors to manage and access ECG data with other clinical data in one platform
  • Medidata’s dynamic monitoring solution to support risk-based monitoring
  • Additional integration capabilities for clinical trial management through XML interoperability
  • New enhancements to Medidata’s coding solution

Connect with Medidata

About Medidata Solutions

Medidata Solutions is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud™ brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,815.07 +36.92 0.21%
S&P 500 2,069.64 +8.41 0.41%
NASDAQ 4,762.1210 +13.7250 0.29%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs